InvestorsHub Logo
Followers 8
Posts 1911
Boards Moderated 0
Alias Born 09/10/2012

Re: None

Tuesday, 01/31/2023 7:28:51 AM

Tuesday, January 31, 2023 7:28:51 AM

Post# of 3283
ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results

-- Preliminary unaudited Q4 2022 net sales expected to be approximately $10 million --

-- Cash, cash equivalents and marketable securities of $75 million at 12/31/2022, which is expected to extend cash runway through 2024 -

very good
Bullish
Bullish